Dr. Larrick is a biotech pioneer. His work on therapeutic antibodies and protein therapeutics has spanned the entire range of biopharmaceutical product development from target discovery, process science to advanced clinical trials. Larrick was a founding scientist and Director of Research at Cetus, one of the earliest biotech companies, starting in 1982. Cetus became Chiron, which was acquired by Novartis for $5.1 billion. While at Cetus, he developed technologies critical to the practical development of recombinant antibodies as a new class of biotherapeutics. In 1991, Larrick founded the Panorama Research Institute (PRI). The PRI team has discovered and initiated development of a diverse and innovative portfolio of drug candidates addressing major unmet needs in cancer, infectious, autoimmune, cardiovascular, neurological and metabolic diseases. PRI has incubated more than 20 life science projects. To date, PRI-initiated companies have led to five IPOs and numerous successful acquisitions. Larrick holds M.D. and Ph.D. degrees from Duke University School of Medicine.